Abstract
GENERAL COMMENTARY article Front. Immunol., 07 January 2013Sec. Vaccines and Molecular Therapeutics Volume 3 - 2012 | https://doi.org/10.3389/fimmu.2012.00409
Highlights
Alessandro Ottaiano 1*, Maurizio Capuozzo 2, Guglielmo Nasti 1, Piera Maiolino 3, Valentina De Angelis 4, Stefania Scala 5 and Rosario V
Randomized trials with anti-Epidermal Growth Factor Receptor (EGFR) antibodies have shown a significant impact of KRAS [wild type vs. mutated] on response and prognosis: the presence of KRAS activating mutations was found to be associated with reduced biological and clinical activity for the treatment
Both antibody-dependent cell-mediated cytotoxicity (ADCC) and cetuximabinduced macrophage responses can be more pronounced for FcγRIIIa 158-Val carriers (Tsuchiya et al, 2007; Pander et al, 2011)
Summary
Alessandro Ottaiano 1*, Maurizio Capuozzo 2, Guglielmo Nasti 1, Piera Maiolino 3, Valentina De Angelis 4, Stefania Scala 5 and Rosario V. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development by Eng, C. One of the most successfully approach in the treatment of metastatic colorectal cancer (mCRC) is the inhibition of the Epidermal Growth Factor Receptor (EGFR) pathway by antibodies (cetuximab and panitumumab).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
